• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Multiple Sclerosis/ Demyelinating Disease  • Dermatology  • Melanoma  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Monica M. Madray, MD; John F. Greene Jr, MD; David F. Butler, MD

Arch Neurol. 2008;65(10):1378-1379.

Objective  To report the association of the development of a primary, cutaneous, anaplastic large-cell lymphoma after initiation of glatiramer acetate treatment of a patient with relapsing-remitting multiple sclerosis.

Design  Case report.

Setting  Dermatology outpatient clinic.

Patient  A 33-year-old white woman developed an erythematous nodule on her leg 4 months after starting treatment with glatiramer acetate. Biopsy showed primary, cutaneous, anaplastic large-cell lymphoma. Further evaluation showed no systemic involvement.

Intervention  Radiation therapy induced a complete remission.

Conclusions  Several T-cell–mediated skin conditions have been associated with the use of glatiramer acetate, such as pseudolymphoma, drug eruptions, and erythema nodosum. We report the association of a T-cell malignancy with the use of glatiramer acetate.

Author Affiliations: Departments of Dermatology (Drs Madray and Butler) and Pathology (Dr Greene), Scott and White Memorial Hospital and Clinic, Temple, Texas.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Lessons learned from long-term multiple sclerosis treatment trials
Marriott and O'Connor
Mult Scler 2010;16:1028-1030.